Author  
Place of duty  
Title   전이성 악성흑색종에 대한 Dimethyl Triazeno Imidazole Carboxamide ( DTC ) 의 치료효과 ( Dimethyl Triazeno Imidazole Carboxamide ( DTIC ) Therapy in Metastatic Malignant Melanoma )
Publicationinfo   1987 Jan; 019(02): 95-101.
Key_word  
Full-Text  
Abstract   Twenty-six patients with metastatic malignant melanoma were treated with dimethyl triazeno imidazole carboxamide (DTIC), at a dose of 250 mg/m' intravenously daily for 5 days every 3 weeks. Six of 26(23%) patients achieved partial remission with a median response duration of 15 weeks. The median survival from onset of thereapy was 28 weeks for all patients and 45 weeks for those who responded to chemotherapy. Toxicity was acceptable and easily controlled.
저 자   박근칠(Keun Chil Park),강윤구(Keun Chil Park),이재훈(Jae Hoon Lee),김승택(Seung Taek Kim),방영주(Yung Jue Bang),김노경(Noe Kyeong Kim)